Treatment of virus-infected cultures with the Bcl-xL antagonist A-1331852 resulted in a reduction in size of foci of infection as assessed by the number of infected nuclei per cluster, the FFU cluster area, the FFU cluster perimeter, and the FFU cluster convex hull. The gene discussed is BCL2L1; the disease is infection.